IASLC TTLC 2024 | Targeting SMARCA4 mutations in lung cancer

Jia Luo, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the disease biology and treatment options under development for SMARCA4-mutant lung cancer, which occurs in approximately one in ten patients. The SMARCA4 gene encodes BRG1, which regulates gene expression, and a novel therapeutic, which targets SMARCA2, is under investigation. Due to synthetic lethality, targeting SMARCA2 will potentially benefit SMARCA4-mutant lung cancer. This interview took place at 2024 Targeted Therapies of Lung Cancer Meeting (TTLC 2024) in Santa Monica, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.